2023042 公司点评报告 ·医药行业 24Q2 利润高速增长,流水线驱动未来成长 2024 年中报业绩点评 核心观点 ● 事件:公司发布 2024年半年度报告,2024年 1~6 月实现营业收入 12.79 亿 元（-7.37%），归母净利润 2.02 亿元（+15.38%），扣非净利润 1.99 亿元 (+11.49%),经营性现金流 2.13 亿元(-48.09%)。2024Q2 实现营业收入 6.63 亿元(-5.93%),归母净利润 0.81 亿元(+40.32%),扣非净利润 0.81 亿元(+39.45%),经营性现金流 2.08 亿元(-14.37%)。 ● 自主产品增长驱动业绩改善,代理产品业务进一步剥离:1自主产品:2024 年 1-6 月公司自主产品业务实现销售收入 9.32 亿元(+7.61%),收入占比已 由 2019年的 37.73%提升至 72.91% (+35.18pct)，净利润贡献已由 2019年 的 75.27%提升至 87.24%(+11.97pct); 2024H1 自主试剂产品销量同比增 长 23.4%,实现收入 8.59 亿元(+5.9%),毛利率 72.42% ...

Investment Rating - The report maintains a "Buy" rating for the company [4][5]. Core Views - The company continues to increase R&D investment and market promotion of its product lines, while also enhancing management efficiency and cost reduction, leading to stable performance and an increase in the proportion of self-developed products [2][4]. Financial Summary - For H1 2024, the company achieved operating revenue of 1.279 billion yuan (down 7.37%), net profit attributable to the parent company of 202 million yuan (up 15.38%), and non-recurring net profit of 199 million yuan (up 11.49%). Operating cash flow was 213 million yuan (down 48.09%) [4][5]. - The sales revenue of self-developed products in H1 2024 was 932 million yuan (up 7.61%), with a gross margin of 72.42% (up 1.54 percentage points). The sales revenue of agency products was 334 million yuan (down 32.69%), with a gross margin of 13.68% (down 7.75 percentage points) [4][5]. - The proportion of self-developed products in total revenue increased from 37.73% in 2019 to 72.91% in H1 2024, with their contribution to net profit rising from 75.27% in 2019 to 87.24% [4][5]. Product Development and Market Expansion - New products have been approved, and the promotion of automated testing lines is progressing smoothly, driving an increase in reagent sales. In H1 2024, the company achieved a shipment of 2,301 units of large instruments and testing lines, with reagent sales volume increasing by 23.4% year-on-year [4][5]. - The company is actively promoting the intelligent laboratory testing analysis pipeline and collaborating with various platform terminals, which is expected to lead to sustained growth in reagent sales [4][5]. Earnings Forecast - The report maintains EPS forecasts for 2024, 2025, and 2026 at 0.71 yuan, 0.86 yuan, and 1.05 yuan respectively, with a target price of 17.27 yuan, corresponding to a PE ratio of 24X for 2024 [4][5].

Investment Rating - The report maintains a "Buy" rating for the company [4][10]. Core Views - The company reported a revenue of 1.279 billion yuan in the first half of 2024, a year-on-year decline of 7.37%. However, the net profit attributable to shareholders increased by 15.38% to 202 million yuan, and the net profit after deducting non-recurring items grew by 11.49% to 199 million yuan [2][6]. - The decline in revenue is primarily due to the gradual divestment of agency business, which has put short-term pressure on performance. In contrast, revenue from self-produced reagents increased by 5.9% to 859 million yuan, with sales volume rising by 23.4% [7]. - The company has seen a significant increase in the installation of production lines, with 109 biological immune production lines and 110 blood production lines installed in the first half of 2024, which is expected to continue driving reagent sales [7][9]. - The gross profit margin improved to 57.00%, up by 3.62 percentage points, attributed to effective cost control. The net profit margin also increased to 15.83%, up by 3.39 percentage points [9]. - The company is focusing on research and development, with a slight increase in R&D expenses and marketing efforts. New products, including the i6000 chemiluminescence analyzer and C2000 fully automated biochemical analyzer, have been registered, enhancing the product matrix [9]. Financial Summary - The company expects revenues for 2024, 2025, and 2026 to be 3.007 billion, 3.321 billion, and 3.767 billion yuan, respectively, with year-on-year growth rates of 3.85%, 10.43%, and 13.44% [10]. - The net profit attributable to shareholders is projected to be 370 million, 494 million, and 680 million yuan for the same years, with growth rates of 18.36%, 33.49%, and 37.66% [10]. - Earnings per share (EPS) are expected to be 0.60, 0.81, and 1.11 yuan for 2024, 2025, and 2026, respectively [10].

证券代码:300463 证券简称:迈克生物 迈克生物股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |------------|-----------------------|-------------|------------------| | | | | 编号：2024-IR003 | | | □特定对象调研 | ■分析师会议 | | | 投资者关系 | □媒体采访 □业绩说明会 | | | | 活动类别 | □新闻发布会 □路演活动 | | | | | □现场参观 | | | □其他（请文字说明其他活动内容） 华泰证券、国信证券、国联证券、国盛证券、东方证券、中信建投证券、中信 证券、中金公司、华安证券、华鑫证券、国投证券、野村证券、长江证券、银 河证券、太平洋证券、方正证券、申万宏源证券、国泰君安证券、建信养老金 参与单位名称 管理有限责任公司、东方证券资产管理有限公司、高毅资产、源峰基金、相聚 资本、长信基金、国盛资管、灏浚投资、众信资产、凯丰投资、北京弘道投 资、华强金控、APS 资产管理、康曼德资本共 32 家机构的 42 名参会人员。 时间 2024 年 ...

Investment Rating - The report maintains a "Recommended" rating for the company, indicating a positive outlook for its stock performance relative to the market [1]. Core Insights - The company reported a revenue of 1.279 billion yuan for the first half of 2024, a decrease of 7.37% year-on-year, while the net profit attributable to shareholders increased by 15.38% to 202 million yuan [1]. - The growth in self-developed products has driven performance improvement, with self-developed product sales reaching 932 million yuan, accounting for 72.91% of total revenue, up from 37.73% in 2019 [1]. - The company is actively advancing its laboratory automation solutions, which are expected to provide long-term growth momentum [1]. - Continuous investment in technological innovation is emphasized, with 25-30% of annual net profit allocated to R&D, totaling over 1.5 billion yuan in the last five years [1]. Financial Performance Summary - For the first half of 2024, the company achieved a gross profit margin of 57.00%, an increase of 3.62 percentage points year-on-year [1]. - The projected financial metrics for 2024-2026 include a net profit of 450.92 million yuan in 2024, representing a growth of 44.24% [5][9]. - The expected earnings per share (EPS) for 2024, 2025, and 2026 are 0.74 yuan, 0.92 yuan, and 1.14 yuan, respectively [5][9]. Strategic Focus - The company is focusing on enhancing its product portfolio and maintaining a comprehensive strategy across various platforms, including biochemical, immunological, and molecular diagnostics [1]. - The report highlights the importance of the company's automation solutions in driving the rapid growth of self-developed products [1].

Investment Rating - The report maintains a "Buy" rating for the company [3][8]. Core Views - The company's revenue for 1H24 reached 1.279 billion RMB, a year-on-year decrease of 7.4%, while net profit attributable to shareholders was 202 million RMB, an increase of 15.4% year-on-year. The revenue from self-developed products grew by 7.6% year-on-year, indicating steady progress in the core business [3]. - The company achieved a significant increase in the shipment of large instruments and production lines, with a total of 2,301 units/lines shipped in 1H24, representing a year-on-year increase of 43.7% [3]. - The gross margin for 1H24 improved to 57.0%, up 3.6 percentage points year-on-year, primarily due to the higher gross margin of self-developed products, which now account for 72.9% of total revenue [4]. - The report forecasts EPS for 2024-2026 to be 0.71, 0.88, and 1.08 RMB, respectively, and sets a target price of 13.79 RMB based on a sum-of-the-parts (SOTP) valuation method [3][4]. Revenue and Profitability - The company expects a revenue increase in 2024, with projected figures of 3.096 billion RMB, a year-on-year growth of 6.9% [7]. - The net profit attributable to shareholders is projected to be 437 million RMB in 2024, reflecting a year-on-year increase of 39.8% [7]. - The report highlights a strong growth outlook for the chemical luminescence segment, with an anticipated revenue increase of nearly 15% in 1H24 [5]. Business Segments - The chemical luminescence segment is expected to benefit from an increase in instrument installations, leading to accelerated reagent sales [5]. - The clinical testing business saw a nearly 30% year-on-year revenue growth in 1H24, driven by successful promotion of blood cell products [6]. - The agency business experienced a decline, with agency revenue of 334 million RMB in 1H24, down 32.7% year-on-year, as the company continues to reduce its focus on this segment [6].

证券代码:300463 证券简称:迈克生物 公告编号:2024-083 迈克生物股份有限公司 第 1 页 共 3 页 证券代码:300463 证券简称:迈克生物 公告编号:2024-083 一、回购公司股份的进展情况 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号--回购 股份》等相关规定，公司应当在回购期间每个月的前三个交易日内披露截至上月末的回购进 展情况。现将公司股份回购进展情况公告如下： 截至2024年7月31日，公司通过回购专用证券账户以集中竞价交易方式累计回购公司股 份2,954,300股，占公司当前总股本的比例为0.48%，成交均价为12.13元/股，最高成交价为 13.23元/股，最低成交价为10.91元/股，支付的总金额为35,828,060.82元（不含交易费用）。 本次回购符合公司回购股份方案及相关法律法规的要求。 关于回购公司股份的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 迈克生物股份有限公司（以下简称"公司"）于 2024 年 2 月 5 日召开的第五届董事会第十 二次会议、第五届监事会第十一 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2024, with a year-on-year growth of 25%[1]. - The company's operating revenue for the first half of 2024 was ¥1,278,911,868.07, a decrease of 7.37% compared to ¥1,380,723,264.24 in the same period last year[11]. - Net profit attributable to shareholders for the first half of 2024 was ¥201,725,714.09, representing an increase of 15.38% from ¥174,836,659.46 in the previous year[11]. - The basic earnings per share for the first half of 2024 was ¥0.3320, up 16.29% from ¥0.2855 in the same period last year[11]. - The company reported a significant increase in revenue, achieving a total of 22 million in the first half of 2024, reflecting a growth of 15% compared to the same period last year[22]. - The company reported a strong performance in the first half of 2024, with a focus on improving operational efficiency and product quality[50]. - The company reported a net profit of CNY 107.03 million from its subsidiary Mike Medical Electronics, while another subsidiary, Mike Industry, reported a net loss of CNY 23.17 million[81]. User Growth and Market Expansion - User data showed a 15% increase in active users, reaching a total of 1.5 million users by the end of June 2024[1]. - The company has provided a performance guidance for the second half of 2024, expecting a revenue growth of 20% compared to the first half[1]. - Market expansion efforts have led to a 10% increase in market share in the Asia-Pacific region[1]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence[1]. - The company plans to enhance its digital marketing strategies, aiming for a 50% increase in online sales channels by the end of 2024[1]. - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by the end of 2024[48]. Research and Development - The company is investing heavily in R&D, with a budget increase of 40% for new technology development in 2024[1]. - R&D personnel increased to 1,162, representing 34.24% of total employees, with a total R&D investment of 186.31 million yuan, a 15% increase year-on-year[31]. - The company has 480 ongoing R&D projects across various diagnostic categories, with 38 new projects initiated in the current period[32]. - The company is committed to R&D, with a focus on independent innovation and collaboration, establishing a global resource-based R&D innovation platform[22]. - The company has established an "8+1" product technology platform, covering various diagnostic areas, and aims to meet 80% of project needs in medical institutions with automated solutions[55]. Product Development and Innovation - New product launches contributed to 30% of total sales, indicating strong market acceptance and demand[1]. - The company has successfully launched the i6000 and C2000 automated analyzers, enhancing operational efficiency and customer experience[29]. - The company aims to enhance its market competitiveness by diversifying its product line, including new tests for infectious diseases and metabolic disorders[33]. - The company has developed and registered 14 new coagulation products, enhancing the product menu and increasing market share[35]. - The company is focusing on the development of new immunoassay kits, including those for tumor markers and inflammatory markers, to meet growing market demand[119][121][125]. Financial Management and Investments - No cash dividends will be distributed to shareholders for this fiscal year, as the company focuses on reinvestment for growth[1]. - The company has a total of 1,892 professional technical personnel, with 483 dedicated to customer service, covering over 60% of second-tier cities[61]. - The company has reported a loss of ¥2,741,746.17 from financial assets measured at fair value, with a total investment of ¥81,003,142.75[71]. - The company has allocated ¥44,348.13 million to the IVD product technology R&D center project as part of the cumulative investment of ¥127,620.84 million in raised funds[72]. - The company plans to extend the timeline for the IVD Industrial Park project to June 2025, a delay of 6 months[72]. Regulatory Compliance and Quality Management - The company has obtained environmental impact assessment approvals for all construction projects as required[102]. - The company has a strong focus on quality management, having obtained ISO 13485 and ISO 14001 certifications, ensuring international advanced quality management standards[57]. - The company is committed to maintaining high standards of product quality and compliance with international regulations, as reflected in its extensive registration efforts[41]. - The company has filed for 644 domestic patents and 8 international patents, with 336 being invention patents, showcasing its commitment to innovation[55]. Strategic Partnerships and Collaborations - A strategic partnership was announced with a leading healthcare provider to improve service delivery and customer engagement[1]. - The company has formed partnerships with 593 distributors, expanding its reach to 120 countries and regions, indicating a strong focus on international market development[19]. - The company is actively involved in collaborative research projects with major hospitals, including the development of innovative diagnostic reagents and clinical application studies[24]. Challenges and Risks - The company is facing risks from policy changes in the in vitro diagnostic industry, which could impact its operations if it fails to adapt to new regulations and market rules[86]. - Increased competition in the in vitro diagnostic industry is shifting from product competition to comprehensive solution offerings, necessitating continuous improvement in product quality and service capabilities[87]. - The company emphasizes the importance of talent retention in the technology-intensive in vitro diagnostic sector, implementing measures to stabilize and grow its workforce[89].

证券代码:300463 证券简称:迈克生物 公告编号:2024-082 迈克生物股份有限公司 2024 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第2号——上市公司募集资金管理和使 用的监管要求》（证监会公告〔2022〕15号）、《深圳证券交易所上市公司自律监管指引第2 号—创业板上市公司规范运作》以及《深圳证券交易所创业板上市公司自律监管指南第2号— 公告格式》的相关规定，将迈克生物股份有限公司（以下简称"公司"）2024年半年度募集资 金存放与实际使用情况报告如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于同意迈克生物股份有限公司向特定对象发行股票注册 的批复》（证监许可〔2021〕412 号）的核准，迈克生物股份有限公司（以下简称"公司"）本 次向特定对象发行人民币普通股（A 股）56,000,000 股，每股发行价格为 28.11 元/股，募集资 金总额为人民币 1,574,160,000.00 元，扣除发行费用人 ...

证券代码：300463 证券简称：迈克生物 公告编号：2024-081 迈克生物股份有限公司 第五届监事会第十六次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 一、监事会会议召开情况 1、迈克生物股份有限公司（以下简称"公司"）第五届监事会第十六次会议通知于2024年7 月22日以邮件、短信的方式向全体监事发出并送达。 2、本次监事会于2024年8月1日在公司会议室以现场方式召开。 （一）审议通过《关于公司2024年半年度报告全文及其摘要的议案》 经审核监事会认为：公司董事会对《2024 年半年度报告》及其摘要的编制和审议程序符合 相关法律、法规及公司章程的规定，且 2024 年半年度报告的内容和格式符合中国证监会和深 圳证券交易所的各项规定，所包含的信息真实、准确、完整地反映出公司的经营业绩、财务状 况等情况，不存在任何虚假记载、误导性陈述或重大遗漏，未发现参与半年度报告编制和审议 的人员有违反保密规定的行为。全体监事保证公司 2024 年半年度报告及其摘要所披露的信息 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并对其内容的真实 ...